Ticino Wealth Takes Position in Stryker Corporation $SYK

Ticino Wealth bought a new stake in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,686 shares of the medical technology company’s stock, valued at approximately $944,000.

A number of other large investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Stryker by 0.8% during the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock valued at $12,485,012,000 after purchasing an additional 272,828 shares during the period. Alliancebernstein L.P. increased its stake in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares during the period. Legal & General Group Plc raised its holdings in Stryker by 4.4% during the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock valued at $851,457,000 after buying an additional 96,662 shares during the last quarter. Corient Private Wealth LLC boosted its position in Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after buying an additional 1,146,998 shares during the period. Finally, Invesco Ltd. boosted its position in Stryker by 4.5% during the 3rd quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock valued at $689,404,000 after buying an additional 80,536 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

Stryker stock opened at $335.74 on Tuesday. Stryker Corporation has a fifty-two week low of $319.32 and a fifty-two week high of $404.87. The stock’s 50 day simple moving average is $352.61 and its two-hundred day simple moving average is $359.31. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock has a market cap of $128.58 billion, a price-to-earnings ratio of 40.30, a PEG ratio of 2.01 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the company earned $4.01 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, analysts expect that Stryker Corporation will post 14.92 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is presently 41.90%.

Analysts Set New Price Targets

SYK has been the subject of several recent analyst reports. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a research note on Tuesday, January 6th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Needham & Company LLC increased their price objective on Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Finally, Evercore set a $390.00 target price on Stryker in a research note on Monday, January 5th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $421.11.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.